DBH , DSP
INTERACT DBH DSP
4@CD DSP 4@CD (@( @card@@CD mg/@NN kg@NN I.@NP P.@NP )@) cuased@VVD a@DT decrease@NN in@IN the@DT dopamine-beta-@NN hydroxylase (@( DBH )@) activity@NN in@IN the@DT rat@NN brain@NN and@CC heart@NN .@SENT
AANAT , GALR2 , SFRS2 , TK1
INTERACT SFRS2 TK1
Genomic@JJ clone@NNS span@VVG distal@JJ 17q24-proximal@JJ 17q25@NN be@VBD organize@VVN into@IN a@DT contig@NN with@IN two@CD gap@NNS that@WDT encompass@VVD @card@@CD existing@JJ genetic@JJ marker@NNS ,@, 8@CD know@VVN gene@NNS (@( GALR2 ,@, AANAT ,@, ENVL@NP ,@, SFRS2 ,@, SEC14L@NP ,@, DNAH17@NP ,@, API4@NP ,@, and@CC TK1 )@) ,@, and@CC @card@@CD previously@RB identify@VVN express@VVN sequence@NN tag@NNS .@SENT
SP1 , TFAP2A , TFAP2C
INTERACT TFAP2A SP1
we@PP show@VVP here@RB that@IN/that the@DT proximal@JJ promoter@NN also@RB bind@VVZ AP-2 strongly@RB and@CC specifically@RB to@TO two@CD site@NNS ,@, one@CD of@IN which@WDT overlap@VVZ the@DT Sp1 proximal@JJ suppressor@NN site@NN .@SENT
MPO , SERPINE1
NOT INTERACT MPO SERPINE1
total@JJ content@NN and@CC extracellular@JJ concentration@NN of@IN myeloperoxidase (@( MPO )@) ,@, eosinophil@NN cationic@JJ protein@NN (@( ECP@NP )@) ,@, histamine@NN and@CC plasminogen@NN activator@NN inhibitor-1@NN (@( Pai @card@@CD )@) be@VBD analyse@VVN by@IN Elisa@NP or@CC Ria@NP method@NNS .@SENT
ADRBK2 , GRK5 , GRK6
INTERACT GRK6 ADRBK2
Overexpression@NN of@IN GRK2@NP ,@, GRK3 ,@, GRK5 or@CC GRK6 together@RB with@IN C3aR@NP in@IN COS-7@JJ cell@NNS enhance@VVD the@DT C3a-induced@NP C3aR@NP phosphorylation@NN @card@@CD -@: 1.9-fold@NP (@( p@NN <@NN ;@: @card@@CD )@) ,@, but@CC each@DT kinase reduce@VVD ligand-stimulated@JJ phospholipase@NN C@NP activity@NN differently@RB .@SENT
BIRC5 , SP1
INTERACT BIRC5 SP1
unbiased@JJ mutagenesis@NN analysis@NN of@IN the@DT human@JJ survivin promoter@NN reveal@VVD that@IN/that target@VVG the@DT Sp1 sequence@NNS at@IN position@NN @card@@CD and@CC @card@@CD abolish@VVN basal@JJ transcriptional@JJ activity@NN by@IN approximately@RB @card@@CD %@NN .@SENT
C5 , C6
NOT INTERACT C5 C6
design@NN :@: a@DT three-dimensional@JJ (@( 3D@JJ )@) anatomically@RB accurate@JJ finite@JJ element@NN model@NN comprise@VVG of@IN the@DT C4-@NP C5 -@: C6 cervical@JJ spine@NN unit@NN include@VVG the@DT three@CD vertebra@NNS ,@, two@CD interconnecting@JJ intervertebral@JJ disc@NNS ,@, and@CC the@DT anterior@JJ and@CC posterior@JJ ligament@NN complex@NN be@VBZ use@VVN .@SENT
PLAUR , SERPINB2 , SERPINE1
NOT INTERACT
uPA@NN ,@, uPAR ,@, Pai @card@@CD ,@, and@CC Pai @card@@CD be@VBD consider@VVN as@IN categorical@JJ variable@NNS ,@, each@DT with@IN two@CD cut@NN point@NNS that@WDT be@VBD establish@VVN by@IN isotonic@JJ regression@NN analysis@NN .@SENT
ITGAM , ITGB2
INTERACT ITGAM ITGB2
we@PP find@VVD that@IN/that three@CD selective@JJ inhibitor@NNS of@IN PKC@NP ,@, structurally@RB relate@VVN to@TO staurosporine@NN ,@, largely@RB block@VVD both@DT fMLP-@NN and@CC phorbol@NN 12-myristate@JJ 13-acetate@JJ (@( PMA)-induced@NP L-selectin@NP shedding@NN ;@: however@RB ,@, these@DT inhibitor@NNS do@VVD not@RB affect@VV fMLP-induced@NN up-regulation@NN of@IN Mac-1 (@( CD11b /@SYM CD18 )@) expression@NN ,@, which@WDT have@VHZ be@VBN show@VVN not@RB to@TO involve@VV PKC@NP .@SENT
CDC2 , CDK2 , CDKN1B , CUL3 , SKP1 , SKP2
INTERACT SKP2 CDK2
Biochemical@NP study@NNS show@VVD that@IN/that Skp2 interact@VVZ specifically@RB with@IN cyclin E@NN and@CC thereby@RB promote@VVZ its@PP$ ubiquitylation@NN and@CC degradation@NN both@CC in@IN vivo@JJ and@CC in@IN vitro@NN .@SENT
CD14 , CD68 , FASLG
INTERACT CD14 FASLG
CD14 ,@, a@DT receptor@NN for@IN bacterial@JJ product@NNS such@JJ as@IN lipopolysaccharides@NNS ,@, be@VBD also@RB detect@VVN on@IN a@DT proportion@NN of@IN FasL express@VVG mononuclear@JJ cell@NNS around@IN the@DT damaged@JJ bile@NN duct@NNS in@IN PBC@NP .@SENT
App , THY1
INTERACT App THY1
To@TO tackle@VV this@DT question@NN ,@, we@PP analyse@VVD the@DT expression@NN of@IN both@DT eNOS@NNS and@CC iNOS@NNS in@IN patient@NNS with@IN sporadic@JJ ad@NN ,@, in@IN transgenic@JJ mouse@NNS express@VVG human@JJ amyloid@JJ precursor protein (@( App )@) with@IN the@DT Swedish@JJ double@JJ mutation@NN under@IN control@NN of@IN the@DT Thy1 promotor@NP (@( APP23@NP mouse@NNS )@) ,@, and@CC after@IN electrolytic@JJ cortical@JJ lesion@NN in@IN rat@NN ,@, an@DT experimental@JJ paradigm@NN associate@VVN with@IN elevated@JJ expression@NN of@IN App .@SENT
CDC42 , LPA
INTERACT CDC42 LPA
we@PP show@VVP that@IN/that serum@NN and@CC the@DT serum@NN lipid@NN ,@, lysophosphatidic@JJ acid@NN (@( LPA )@) ,@, increase@VVD Cdc42 GTP@NP level@NNS and@CC trigger@VVD MTOC@NP reorientation@NN in@IN serum-starved@JJ wounded@JJ monolayer@NNS of@IN 3T3@JJ fibroblast@NNS .@SENT
HLA-G , HP
INTERACT HLA-G HP
the@DT adhesion@NN be@VBD partially@RB reverse@VVN by@IN mask@VVG HLA-G on@IN pEC@NN with@IN anti-HLA@NN mAbs@NNS or@CC by@IN mask@VVG the@DT HLA-G -specific@JJ inhibitory@JJ receptor@NN ILT-2@NN on@IN NK@JJ cell@NNS with@IN the@DT mAb@NN HP -F1@NN .@SENT
REL , TF
INTERACT REL TF
electrophoretic@JJ mobility@NN shift@NN assay@NNS from@IN nuclear@JJ extract@VVZ of@IN peripheral@JJ blood@NN mononuclear@JJ cell@NNS reveal@VVD that@IN/that exercise@NN testing@NN increase@VVN NF-kappaB@NP (@( p50/@NN p65@NN )@) binding@JJ activity@NN to@TO a@DT NF-kappaB@NP consensus@NN sequence@NN by@IN @card@@CD +/@NN -@: @card@@CD %@NN (@( P@NN <@NN ;@: @card@@CD )@) but@CC do@VVD not@RB affect@VV NF-kappaB@NP (@( p65/@NP C-@NP Rel )@) bind@VVG to@TO a@DT nonconsensus-kappaB-like@JJ site@NN present@NN in@IN the@DT TF promoter@NN .@SENT
MBP , MOBP
INTERACT MBP MOBP
by@IN morphometric@JJ analysis@NN of@IN the@DT optic@JJ nerve@NN in@IN MOBP -deficient@NN and@CC MBP /@SYM MOBP -double-deficient@NN mouse@NNS ,@, we@PP demonstrate@VVD that@IN/that MOBP play@VVD a@DT role@NN in@IN control@VVG axonal@JJ diameter@NN .@SENT
CCL2 , CXCL12 , IL8RA , IL8RB
INTERACT
we@PP ,@, therefore@RB ,@, investigate@VVD the@DT in@IN vitro@NN effect@NNS of@IN DCA@NP on@IN human@JJ monocyte@NN and@CC neutrophil@JJ response@NNS to@TO classic@JJ chemoattractants@NNS [@SYM fMet-Leu-Phe@NP (@( fMLP@NP )@) ,@, complement@VV fraction@NN 5a@NP (@( C5a@NP )@) ]@SYM ,@, CC@NP chemokine@NP [@SYM monocyte chemoattractant protein-1 (@( MCP-1 /@SYM CCL2 )@) ]@SYM ,@, and/@JJ or@CC CXC@JJ chemokines@NNS [@SYM stromal@JJ cell-derived@JJ factor-1@NN (@( SDF-1alpha/@NP CXCL12 )@) ,@, interleukin @card@@CD (@( IL-8/@NP CXCL8@NP )@) ]@SYM .@SENT
RGS2 , RGS4 , RGS7
NOT INTERACT
To@TO identify@VV the@DT molecular@JJ mechanism@NN involve@VVN in@IN the@DT sensory@JJ experience-induced@JJ neural@JJ development@NN ,@, we@PP perform@VVD a@DT systematic@JJ survey@NN of@IN the@DT localization@NN of@IN mRNAs@NNS encode@VVG three@CD subtype@NNS of@IN the@DT RGSs@NP (@( RGS2 ,@, RGS4 and@CC RGS7 )@) in@IN develop@VVG rat@NN brain@NNS by@IN in@IN situ@NN hybridization@NN through@IN postnatal@JJ day@NN 2@CD (@( P2@NP )@) ,@, P10@NP and@CC P18@NP to@TO adult@NN .@SENT
ERBB2 , HRG , MAPK1 , PRKCD
INTERACT ERBB2 MAPK1
when@WRB MCF-7@JJ cell@NNS be@VBD treat@VVN with@IN E(2@NP )@) in@IN the@DT presence@NN of@IN an@DT anti-@NN HER-2 monoclonal@NN antibody@NN (@( herceptin@NN )@) ,@, @card@@CD %@NN of@IN E(2)-induced@NP Erk activation@NN be@VBZ block@VVN .@SENT
CCR5 , CCR7 , CD27 , CD28 , PTPRC
NOT INTERACT CD28 CD27
previous@JJ study@NNS of@IN perforin@NN expression@NN and@CC cytokine@NN production@NN in@IN subset@NNS of@IN peripheral@JJ human@JJ CD45RA(-)CD8(+@NN )@) T@NN cell@NNS with@IN different@JJ CD28 /@SYM CD27 phenotype@NNS show@VVD that@IN/that CD28 (@( +)CD45RA(-)CD8(+@NN )@) and@CC CD27 (@( +)CD45RA(-)CD8(+@NN )@) T@NN cell@NNS have@VHP characteristic@NNS of@IN memory@NN T@NN cell@NNS ,@, whereas@IN CD28 (@( -)CD45RA(-)CD8(+@NN )@) and@CC CD27 (@( -)CD45RA(-)CD8(+@NN )@) T@NN cell@NNS have@VHP characteristic@NNS of@IN both@DT memory@NN and@CC effector@NN T@NN cell@NNS .@SENT
C2 , C3
INTERACT C2 C3
Preoperative@JJ stability@NN of@IN C1-@NP C2 in@IN the@DT reduce@VVN position@NN be@VBD satisfactory@JJ but@CC with@IN regard@NN to@TO iatrogenic@JJ instability@NN the@DT C0-C1@JJ fixation@NN be@VBD combine@VVN with@IN occipitocervical@JJ fussion@NN by@IN Ransford@NP loop@NN extend@VVG over@IN C0-@NP C3 .@SENT
CAV1 , STOM , STOML3
INTERACT STOM STOML3
we@PP identify@VVD a@DT stomatin -related@JJ olfactory@NN protein@NN (@( SRO )@) that@WDT be@VBZ specifically@RB express@VVN in@IN olfactory@JJ sensory@JJ neuron@NNS (@( OSNs@NP )@) .@SENT
CD19 , CD7 , ITGAX , SPN
NOT INTERACT
Tumor@NP cell@NNS be@VBD immunostained@VVN by@IN a@DT panel@NN of@IN antibody@NNS that@WDT identify@VVD CD10@NP ,@, CD43 ,@, CD19 ,@, CD3@NP ,@, CD7 ,@, and@CC MHC@NP class@NN I@PP and@CC II@NP .@SENT
CDKN2A , E2F4 , E2F5 , ETS2
INTERACT ETS2 CDKN2A
here@RB ,@, we@PP report@VVP that@IN/that LMP1@NP promote@VVZ the@DT CRM1-dependent@JJ nuclear@JJ export@NN of@IN Ets2 ,@, which@WDT be@VBZ an@DT important@JJ transcription@NN factor@NN for@IN p16INK4a gene@NN expression@NN ,@, thereby@RB reduce@VVG the@DT level@NN of@IN p16INK4a expression@NN .@SENT
MLH1 , MSH2
NOT INTERACT MLH1 MSH2
thus@RB ,@, 2@CD highly@RB unstable@JJ pediatric@JJ case@NNS show@VVD no@DT detectable@JJ MLH1 /@SYM MSH2 protein@NNS .@SENT
CDKN1A , PIK3CG , PRKCE , SP1
INTERACT CDKN1A SP1
we@PP previously@RB report@VVD that@IN/that the@DT activation@NN of@IN p21 (@( WAF1 /@SYM Cip1 )@) transcription@NN by@IN histone@NN deacetylase@NN inhibitor@NN apicidin@NN be@VBD mediate@VVN through@IN Sp1 site@NNS and@CC point@VVD to@TO the@DT possible@JJ participation@NN of@IN protein@NN kinase C@NP (@( PKC@NP )@) .@SENT
HLA-A , HLA-B
NOT INTERACT HLA-A HLA-B
the@DT author@NNS follow@VVD the@DT frequency@NN of@IN error@NNS in@IN serologic@JJ identification@NN of@IN HLA-A and@CC HLA-B antigen@NNS .@SENT
EBP , MYC
NOT INTERACT EBP MYC
the@DT promoter@NN region@NN contain@VVZ consensus@NN binding@JJ site@NNS for@IN the@DT transcriptional@JJ regulator@NNS Myc and@CC C/@NP EBP beta@NN .@SENT
ABCB1 , ADM
INTERACT ABCB ADM
method@NNS :@: the@DT expression@NN of@IN mdr-1@NN and@CC p-glycoprotein@NN (@( p-gp )@) be@VBD study@VVN by@IN confocal@JJ laser@NN microscope@NN (@( Confocal@NP )@) ,@, RT-PCR@NP and@CC Western@NP blot@VVP analysis@NN in@IN adriamycin-resistant@JJ human@JJ ovarian@JJ cancer@NN cell@NN line@NN (@( A2780/@NP ADM )@) and@CC adriamycin-sensitive@JJ one@CD (@( A2780@NP )@) .@SENT
BLM , RAD51 , WRN
NOT INTERACT
crossover@NNS be@VBP rare@JJ (@( 5@CD %@NN )@) ,@, but@CC delete@VVG the@DT BLM /@SYM WRN homolog@NN ,@, SGS1@JJ ,@, or@CC the@DT SRS2@NP helicase increase@VVZ crossover@NNS @card@@CD to@TO 3-fold@NN .@SENT
CCL2 , CCL3 , CCL4 , MIP
NOT INTERACT MIP CCL2
we@PP report@VVP here@RB that@DT estrogen@NN significantly@RB decrease@VVZ level@NNS of@IN the@DT chemokines@NNS MIP -1alpha@NN and@CC MCP-1 /@SYM Je@NP in@IN murine@JJ mammary@JJ tissue@NN .@SENT
C2 , MAPK1 , PIK3CG , PTGS2 , Src
INTERACT MAPK1 SRC
assay@NNS with@IN inhibitor@NNS and@CC antibody@NNS against@IN protein@NNS involve@VVN in@IN signal@NN transduction@NN demonstrate@VVD that@IN/that NAPS@NP and@CC Taps@NP elevate@VVD COX-2@JJ expression@NN via@IN tyrosine@NN kinase ,@, src ,@, PI-3@NP kinase and@CC PKC@NP ,@, follow@VVN by@IN ERK activation@NN .@SENT
CYP19A1 , HP
INTERACT CYP19A1 HP
the@DT songbird@NN HP express@VVZ high@JJ level@NNS of@IN aromatase (@( estrogen@NN synthase@NN )@) ,@, suggest@VVG that@IN/that locally@RB generate@VVN steroid@NN may@MD affect@VV excitatory@JJ pathway@NNS .@SENT
NGF , TRPA1 , TRPM8
NOT INTERACT TRPM8 TRPA1
take@VVN together@RB these@DT finding@NNS support@VVP a@DT picture@NN in@IN which@WDT TRPM8 be@VBZ the@DT major@JJ player@NN in@IN detect@VVG gentle@JJ cooling@NN ,@, while@IN TRPA1 do@VVZ not@RB seem@VV to@TO be@VB involve@VVN in@IN cold@JJ sense@VVG by@IN Mi@NP neuron@NNS ,@, at@IN least@JJS in@IN the@DT temperature@NN range@NN between@IN @card@@CD and@CC @card@@CD degree@NNS C.@NP
IL10 , Nodal
INTERACT IL10 Nodal
the@DT logistic@JJ regression@NN analysis@NN show@VVD advanced@JJ nodal involvement@NN to@TO be@VB the@DT major@JJ parameter@NN affect@VVG the@DT expression@NN of@IN IL-10 (@( p@NN =@SYM @card@@CD )@) .@SENT
CD14 , CD163 , CD1A , CD80 , ITGAL , SLA
NOT INTERACT
the@DT CD163 (@( +@SYM )@) CD14 (@( -@: )@) SLA DR(+@NP )@) subset@NN produce@VVZ high@JJR amount@NNS of@IN TNF-alpha@NP than@IN the@DT CD163 (@( -@: )@) CD14 (@( +@SYM )@) SLA DR(-@NP )@) subset@NN ,@, whereas@IN CD163 (@( +@SYM )@) CD14 (@( +@SYM )@) SLA DR(+@NP )@) and@CC CD163 (@( -@: )@) CD14 (@( +@SYM )@) SLA DR(+@NP )@) subset@NNS show@VVP intermediate@JJ value@NNS .@SENT
CCND1 , MYC
NOT INTERACT CCND1 MYC
Thirty-three@NP of@IN the@DT successfully@RB karyotyped@JJ fibroadenomas@NNS be@VBD further@RBR investigate@VVN for@IN the@DT presence@NN of@IN amplification@NNS in@IN the@DT CCND1 ,@, C-@NP MYC and@CC HER/@NP 2-neu@NP gene@NNS by@IN mean@NNS of@IN FISH@JJ analysis@NN .@SENT
GCLC , GCLM
NOT INTERACT GCLC GCLM
GCL@NP be@VBZ a@DT heterodimeric@JJ protein@NN with@IN a@DT catalytic@JJ (@( or@CC heavy@JJ ,@, GCLC )@) subunit@NN and@CC a@DT modulatory@JJ (@( or@CC light@JJ ,@, GCLM )@) subunit@NN .@SENT
CD38 , CREBBP , IRF4 , MUM1 , PAX5 , SDC1
INTERACT SDC1 MUM1
an@DT extensive@JJ immunohistochemical@JJ panel@NN ,@, include@VVG the@DT plasma@NN cell@NN relate@VVN antigen@NNS VS38c@NP ,@, CD38 ,@, CD138 ,@, multiple@JJ myeloma@NN oncogene-1-protein@NN (@( MUM1 /@SYM IRF4 )@) ,@, and@CC CREB binding protein (@( CBP )@) be@VBD perform@VVN .@SENT
Coil , MSC
NOT INTERACT Coil MSC
background@NN :@: a@DT non-invasive@JJ eye@NN track@VVG system@NN ,@, base@VVN on@IN pulse@VVN infrared@JJ light@NN (@( IR@NP )@) ,@, be@VBD compare@VVN with@IN the@DT magnetic@JJ scleral@JJ search@NN coil method@NN (@( MSC )@) for@IN saccadic@JJ eye@NN movement@NN recording@NNS .@SENT
ITGB2 , PIK3CG , PRKCD , Tat
NOT INTERACT
Deltap85@NP ,@, a@DT dominant-negative@JJ form@NN of@IN the@DT class@NN IA@NN PI3K adaptor@NN subunit@NN ,@, be@VBD fuse@VVN to@TO an@DT HIV-@NP Tat protein@NN transduction@NN domain@NN (@( Tat -Deltap85@NN )@) .@SENT
ERBB2 , GRB7 , Src
INTERACT GRB7 ERBB2
growth@NN factor@NN receptor@NN bind protein 7@CD (@( Grb7 )@) be@VBZ an@DT adaptor@NN protein@NN that@WDT be@VBZ co-overexpressed@VVN and@CC form@VVZ a@DT tight@JJ complex@NN with@IN the@DT ErbB2 receptor@NN in@IN a@DT number@NN of@IN breast@NN tumour@NNS and@CC breast@NN cancer@NN cell@NN line@NNS .@SENT
SCN1A , SCN2A , SCN3A
INTERACT SCN1A SCN2A
SCN1A be@VBZ part@NN of@IN the@DT SCN1A -@: SCN2A -@: SCN3A gene@NN cluster@NN on@IN chromosome@NN 2q24@JJ that@WDT encode@VVZ for@IN alpha@NN pore@NN form@VVG subunits@NN of@IN sodium@NN channel@NNS .@SENT
CASP2 , CASP8 , CASP9 , CRADD , PML
INTERACT CASP2 PML
here@RB we@PP present@JJ evidence@NN that@IN/that caspase @card@@CD be@VBZ localize@VVN to@TO the@DT promyelocytic leukemia protein@NN nuclear@JJ body@NNS (@( PML -NBs@NNS )@) ,@, nuclear@JJ macro-molecular@JJ complex@NNS that@WDT be@VBP involve@VVN in@IN many@JJ scenario@NNS of@IN apoptosis@NN include@VVG DNA@NN damage@NN .@SENT
CDC2 , Src
INTERACT CDC2 Sr
Recent@JJ technology@NNS and@CC investigation@NNS of@IN interact@VVG protein@NNS have@VHP show@VVN that@DT activation@NN of@IN several@JJ kinase@NNS include@VVG protein@NN kinase@NN A@NP ,@, protein@NN kinase@NN C@NP (@( PKC@NP )@) ,@, p34(@JJ cdc2 )/@NN cyclin@NN B@NP kinase@NN ,@, casein@NN kinase@NN 1@CD (@( CK1@JJ )@) ,@, mitogen-activated@JJ protein@NN kinase@NN (@( MAPK@NP )@) and@CC pp60(@JJ src )@) kinase@NN can@MD lead@VV to@TO phosphorylation@NN of@IN the@DT majority@NN of@IN the@DT @card@@CD serine@NN and@CC two@CD of@IN the@DT tyrosine@NN residue@NNS in@IN the@DT C-terminal@JJ region@NN of@IN Cx43@NP .@SENT
HPRT1 , Kras , TP53
NOT INTERACT Kras TP53
the@DT mutation@NNS C742T@NP ,@, G746T@NP ,@, G747T@NP in@IN the@DT TP53 gene@NN and@CC G35T@NP in@IN the@DT Kras gene@NN have@VHP be@VBN repeatedly@RB find@VVN in@IN sector@NNS of@IN human@JJ tumor@NNS by@IN direct@JJ DNA@NP sequencing@NP .@SENT
TGFB1 , THBS1
INTERACT TGFB1 THBS1
background@NN :@: TGF-beta1 bioactivation@NN ,@, consequent@JJ to@TO the@DT interaction@NN of@IN latent@JJ TGF-beta1 with@IN thrombospondin @card@@CD (@( TSP @card@@CD )@) ,@, correlate@VVZ with@IN matrix@NN accumulation@NN in@IN mesangial@JJ cell@NNS .@SENT
HPR , PHB , PTS
NOT INTERACT HPR PHB
the@DT function@NNS of@IN these@DT HPr -@: and@CC enzyme@NN I-like@JJ protein@NNS in@IN the@DT metabolism@NN of@IN PHB be@VBP still@RB unknown@JJ .@SENT
CP , CYP11A1 , Star
INTERACT CYP11A1 STAR
therefore@RB ,@, to@TO determine@VV the@DT mechanism@NNS involve@VVN in@IN the@DT ovarian@JJ steroidogenesis@NN impairment@NN ,@, in@IN this@DT present@JJ study@NN we@PP evaluate@VVD the@DT ovarian@JJ expression@NN of@IN the@DT essential@JJ steroidogenesis@NN component@NNS :@: cytochrome@NN P450@JJ side@NN cholesterol@NN chain@NN cleavage@NN enzyme@NN (@( P450scc )@) and@CC steroidogenic acute regulatory protein (@( Star )@) .@SENT
ace , APOE
INTERACT ace APOE
DD-33@NP and@CC ID-23@NP combination@NNS (@( ace -@: APOE )@) show@VVD high@JJR odd@NNS of@IN @card@@CD and@CC @card@@CD ,@, respectively@RB .@SENT
PIK3CG , Src
NOT INTERACT PIK3CG Src
inhibitor@NNS of@IN phosphatidylinositide@NN @card@@CD kinase ,@, extracellular@JJ signal-regulated@JJ kinase (@( ERK@NP )@) ,@, and@CC Src kinase reduce@VVD the@DT adhesion@NN and@CC migration@NN of@IN VSMCs@NP on@IN betaig-h3@NN .@SENT
camp , NEDD4 , SGK1
INTERACT NEDD4 SGK1
we@PP previously@RB demonstrate@VVD that@IN/that @card@@CD specifically@RB bind@VVZ one@CD of@IN the@DT E3@NP enzyme@NNS ,@, Nedd4 @card@@CD (@( a@DT human@JJ gene@NN product@NN of@IN KIAA0439@NP ,@, term@VVN hNedd4-2@NN )@) ,@, which@WDT can@MD be@VB phosphorylated@JJ by@IN serum@NN glucocorticoid-inducible@JJ protein@NN kinase 1@CD (@( SGK1 )@) ;@: this@DT bind@VVG protect@VVZ the@DT phosphorylated/@JJ inactive@JJ hNedd4-2@NN from@IN phosphatase-catalyzed@JJ dephosphorylation@NN [@SYM Ichimura@NP ,@, T.@NP ,@, et@NP al@NP .@SENT
FANCC , FANCD2 , FANCG
INTERACT FANCC FANCG
FANCC and@CC FANCG disruption@NN also@RB result@VVD in@IN increase@VVN clastogenic@JJ damage@NN on@IN irradiation@NN ,@, but@CC only@RB FANCG disruption@NN cause@VVD a@DT subsequent@JJ decrease@NN in@IN relative@JJ survival@NN .@SENT
BCAR1 , CRK , Src
INTERACT SRC BCAR1
inhibition@NN of@IN Src kinase@NN be@VBZ show@VVN to@TO reduce@VV tamoxifen-promoted@JJ p130Cas /@SYM BCAR1 phosphorylation@NN and@CC reduce@VV cell@NN viability@NN .@SENT
TFE3 , TFEB
NOT INTERACT TFE3 TFE
Childhood-characteristic@JJ renal@JJ carcinoma@NNS associate@VVN with@IN chromosome@NN translocation@NNS have@VHP be@VBN recognize@VVN (@( genetic@JJ fusion@NN TFE3 or@CC TFEB )@) ,@, as@RB well@RB as@IN the@DT family@NN form@NNS of@IN renal@JJ carcinoma@NN .@SENT
MYF6 , PAX7 , TPM3
INTERACT PAX7 MYF6
marker@NNS indicative@JJ of@IN satellite@JJ cell@NN number@NN ,@, activate@VVN satellite@NN cell@NNS and@CC immature@JJ fiber@NNS include@VVG M-Cadherin@NP ,@, MyoD@NP ,@, desmin@NN ,@, Pax7 and@CC Myf6 be@VBD elevated@JJ by@IN western-blot@NN analysis@NN or@CC immunohistochemistry@NN .@SENT
NPLOC4 , UFD1L , VCP
INTERACT UFD1L NPLOC4
the@DT VCP (@( Ufd1 -@: Npl4 )@) complex@NN mediate@VVZ retrotranslocation@NN of@IN emerge@VVG ER@JJ protein@NNS .@SENT
C3 , GPR4 , Lum , MYLK2 , Rho , RHOA
INTERACT GPR4 RHOA
To@TO investigate@VV potential@JJ signal@VVG mechanism@NNS ,@, the@DT siRNA-mediated@JJ knockdown@NN of@IN GPR4 also@RB prevent@VVD LPC-induced@NP RhoA activation@NN .@SENT
ABCA1 , LCAT , SCARB1
NOT INTERACT LCAT ABCA1
together@RB these@DT finding@NNS indicate@VVP that@IN/that hypercholesterolemia@NP and@CC LpX@NP formation@NN associate@VVN with@IN obstructive@JJ cholestasis@NNS be@VBP correlate@VVN with@IN an@DT increase@NN in@IN hepatic@JJ cholesterol@NN synthesis@NN and@CC be@VBP independent@JJ of@IN plasma@NN HDL@NP level@NNS ,@, LCAT activity@NN ,@, VLDL@NP synthesis@NN ,@, and@CC ABCA1 and@CC SR-BI expression@NN .@SENT
ace , ACE2 , ANG
NOT INTERACT
so@IN ACE2 -angiotensin1-7-@NN Mas@NP axis@NN be@VBD consider@VVN a@DT negative@JJ regulation@NN in@IN renin@NN angiotensin system@NN (@( Ras@NP )@) ,@, and@CC its@PP$ significance@NN have@VHZ be@VBN implicate@VVN into@IN hypertension@NN and@CC other@JJ cardiovascular@JJ disease@NNS .@SENT
INSL3 , RXFP1 , RXFP2
INTERACT INSL3 RXFP1
the@DT human@JJ INSL3 receptor@NN leucine-rich@NN repeat-containing@VVG G@NP protein-coupled@JJ receptor@NN 8@CD (@( LGR8 )@) bind@VVZ INSL3 and@CC relaxin with@IN high@JJ affinity@NN ,@, whereas@IN the@DT relaxin receptor@NN LGR7 only@RB bind@VVZ relaxin .@SENT
BRAF , Kras , MAP2K2
INTERACT BRAF MAP2K2
here@RB ,@, we@PP show@VVP that@IN/that lung-specific@JJ expression@NN of@IN the@DT BRAF V600E@NN mutant@JJ induce@VVZ the@DT activation@NN of@IN extracellular@JJ signal-regulated@JJ kinase (@( ERK)-1/@NP 2@CD (@( MAPK@NP )@) pathway@NN and@CC the@DT development@NN of@IN lung@NN adenocarcinoma@NN with@IN bronchioloalveolar@JJ carcinoma@NN feature@NNS in@IN vivo@RB .@SENT
BCL6 , MTA3 , PRDM1
INTERACT BCL6 MTA3
although@IN the@DT basis@NN for@IN differentiation@NN blockade@NN be@VBZ unknown@JJ in@IN DLBCL@NP ,@, recent@JJ datum@NNS suggest@VVP that@IN/that BCL6 bind@VVG to@TO the@DT MTA3 corepressor@NN might@MD be@VB involve@VVN .@SENT
NGB , Tat
INTERACT NGB Tat
a@DT rat@NN brain@NN Ngb gene@NN be@VBD clon@VVN and@CC fuse@VVN with@IN a@DT gene@NN fragment@NN encode@VVG the@DT nine-amino-acid@JJ Tat PTD@NP (@( transactivator-of-transcription@NN protein-transduction@NN domain@NN ;@: RKKRRQRRR@NP )@) of@IN HIV-1@JJ in@IN a@DT prokaryotic@JJ expression@NN vector@NN to@TO generate@VV a@DT genetic@JJ in-frame@NN N-terminal@NN hexahistidine-tagged@JJ )@) Tat PTD-@NP Ngb fusion@NN protein@NN .@SENT
AR , SELI
NOT INTERACT AR SELI
the@DT reaction@NN of@IN LAl(SeH)2@NP (@( 1@CD )@) with@IN LiN(SiMe3)2@NP result@VVD in@IN the@DT formation@NN of@IN [@SYM LAl(@NP SeLi )2(THF)2@NN ]@SYM (@( 2@LS )@) (@( L@NP =@SYM HC(CMeNAr)2@NP ,@, Ar =@SYM 2,6-iPr2C6H3@JJ )@) .@SENT
LBP , REST
NOT INTERACT LBP REST
the@DT other@JJ high@JJ quality@NN trial@NN compare@VVN advice@NN to@TO stay@VV active@JJ with@IN advice@NN to@TO rest in@IN bed@NN for@IN @card@@CD day@NNS for@IN patient@NNS with@IN sciatic@JJ syndrome@NN ,@, and@CC find@VVD no@DT difference@NNS between@IN the@DT group@NNS .@SENT One@CD of@IN the@DT high@JJ quality@NN trial@NNS also@RB compare@VVN advice@NN to@TO stay@VV active@JJ with@IN exercise@NNS for@IN patient@NNS with@IN acute@JJ simple@JJ LBP ,@, and@CC find@VVD improvement@NN in@IN functional@JJ status@NN and@CC reduction@NN in@IN sick@JJ leave@NN in@IN favour@NN of@IN advice@NN to@TO stay@VV active@JJ .@SENT
ICAM1 , IL18 , TLR2 , TLR4 , TLR9
INTERACT TLR2 TLR9
TLR2 and@CC TLR9 be@VBD report@VVN to@TO be@VB involve@VVN in@IN the@DT induction@NN of@IN CM@NP in@IN a@DT study@NN while@IN recently@RB TLR@NN signal@VVG be@VBD show@VVN to@TO be@VB dispensable@JJ for@IN the@DT development@NN of@IN CM@NP .@SENT
INVS , NPHP1
INTERACT INVS NPHP1
genetic@JJ analysis@NN for@IN INVS disclose@VVD a@DT heterozygous@JJ mutation@NN of@IN TrG@NP at@IN position@NN rs7024375@NN in@IN the@DT 5'UTR@NN of@IN INVS in@IN the@DT patient@NN and@CC his@PP$ mother@NN ,@, while@IN no@DT abnormality@NNS be@VBD find@VVN in@IN any@DT of@IN the@DT @card@@CD exon@NNS of@IN INVS or@CC NPHP1 ,@, 3@CD and@CC 4@CD .@SENT
BMP1 , FGFR1 , IGF1 , NOG , SHOX
NOT INTERACT
the@DT most@RBS notable@JJ regulated@JJ gene@NNS act@VVG on@IN osteoblast@NNS be@VBP :@: NOG ,@, SHOX ,@, IGF1 ,@, BMP1 and@CC FGFR1 .@SENT
fat , PIGS
NOT INTERACT fat PIGS
the@DT objective@NN of@IN this@DT experiment@NN be@VBD to@TO examine@VV the@DT regulation@NN of@IN body@NN composition@NN and@CC lipid@NN metabolism@NN in@IN pig fed@NN low-@NN and@CC high-@NN fat milk@NN formula@NNS supplement@VVN with@IN CLA@NP .@SENT
HFE , TF , TFRC
INTERACT HFE TF
Hemochromatosis be@VBZ cause@VVN by@IN mutation@NNS in@IN HFE ,@, a@DT protein@NN that@WDT compete@VVZ with@IN transferrin (@( TF )@) for@IN bind@VVG to@TO transferrin receptor@NN 1@CD (@( TFR1 )@) .@SENT
C2 , C5 , C6
INTERACT C5 C6
Methyl@NP alpha-gentiobioside@NN (@( methyl@NN 6-O-beta-D-glucopyranosyl-alpha-D-glucopyranoside@NN )@) show@VVZ great@JJR flexibility@NN at@IN the@DT psi-torsion@NN than@IN the@DT other@JJ disaccharide@NNS ,@, but@CC the@DT population@NN distribution@NN around@IN the@DT C5 -@: C6 bond@NN be@VBZ essentially@RB unaffected@JJ by@IN substitution@NN .@SENT
CD28 , CD4 , TNF
NOT INTERACT
H1-specific@JJ T@NN cell@NN clone@NNS from@IN patient@NNS and@CC control@NNS show@VVD a@DT CD4 +@SYM CD28 +@SYM phenotype@NN and@CC a@DT Th1@JJ cytokine@NN profile@NN .@SENT
CASP1 , CD4 , FOXP3 , IL13 , TGFB1
INTERACT IL13 CASP1
IL-13 KO@NP mouse@NNS have@VHD increase@VVN caspase @card@@CD activation@NN ,@, lead@VVG to@TO increase@VVN production@NN of@IN both@DT IL-1beta@NP and@CC IL-18@NP .@SENT
CS , Gal , TERT
INTERACT TERT GAL
Sialylation@NN of@IN 2-(trimethylsilyl)ethyl@JJ 6-O-@JJ tert -butyldiphenylsilyl-beta-D-galactopyranoside@NN (@( 3f@NP )@) give@VVD the@DT good@JJS result@NN ,@, and@CC the@DT resultant@JJ Neu5Ac@NP alpha(2--@NN >@NN ;@: 3@LS )@) Gal disaccharide@NN be@VBD successfully@RB use@VVN in@IN the@DT synthesis@NN of@IN ganglioside@NP GM3@NP .@SENT
CTNNB1 , DKK1 , DKK2 , DKK3 , DKK4 , KREMEN2
NOT INTERACT CTNNB1 DKK1
in@IN colorectal@JJ cancer@NNS with@IN beta-catenin over-expression@NN ,@, Dkk-1 expression@NN level@NNS be@VBD significantly@RB low@JJR in@IN those@DT with@IN lymph@NN node@NN metastasis@NNS than@IN in@IN those@DT without@IN .@SENT
C6 , Camp , LOC100137047-PL , VIP
INTERACT VIP CAMP
in@IN contrast@NN to@TO the@DT well-expressed@JJ PACAP-38@NN and@CC VIP effect@NNS on@IN cAMP production@NN in@IN C6 cell@NNS ,@, helodermin@NN and@CC secretin@NN be@VBD poorly@RB active@JJ as@IN camp stimulator@NNS in@IN this@DT cell@NN line@NN ,@, display@VVG some@DT activity@NN only@RB at@IN a@DT high@JJ 5-microM@NP dose@NN .@SENT
ABI1 , C9orf156 , CDC42 , DIAPH2 , EGF
INTERACT EGF ABI1
Consistently@NP ,@, the@DT ability@NN of@IN EGF ,@, Cdc42 and@CC serum@NN to@TO induce@VV mDia2-dependent@JJ formation@NN of@IN filopodia@NN be@VBZ increase@VVN in@IN the@DT absence@NN of@IN either@CC the@DT WAVE/@NP Abi1 /@SYM Nap1 /@SYM PIR121@JJ (@( WANP@NP )@) or@CC the@DT Arp2/@NP 3@CD complex@NN .@SENT
HPRT1 , PGK1
NOT INTERACT HPRT1 PGK1
this@DT interpretation@NN be@VBZ confirm@VVN by@IN the@DT methylation@NN pattern@NNS of@IN the@DT hypoxanthine@NN phosphoribosyltransferase gene@NN (@( HPRT )@) ,@, map@VVN on@IN Xq26@NP ,@, which@WDT correspond@VVZ to@TO that@DT of@IN an@DT active@JJ gene@NN ,@, whereas@IN that@IN/that of@IN phosphoglycerate@JJ kinase (@( PGK1 )@) ,@, which@WDT remain@VVD on@IN the@DT der(X@NN )@) ,@, correspond@VVZ to@TO that@DT of@IN an@DT inactive@JJ gene@NN .@SENT
ARF1 , ARF3 , KIF21A
INTERACT ARF1 KIF21A
Interfering@NN with@IN cyclic@JJ activation@NN and@CC inactivation@NN of@IN ARF1 by@IN overexpressing@VVG constitutively@RB active@JJ ARF1 (@( Q71L@NP )@) or@CC dominant@JJ inactive@JJ ARF1 (@( T31N@NP )@) alter@VVD the@DT distribution@NN of@IN BIG1@JJ as@RB well@RB as@IN its@PP$ interaction@NN with@IN KIF21A .@SENT
impact , PAH
NOT INTERACT impact PAH
although@IN obesity@NN ,@, dyslipidemia@NN and@CC insulin@NN resistance@NN (@( IR@NN )@) be@VBP well@RB know@VVN risk@NN factor@NNS for@IN systemic@JJ cardiovascular@JJ disease@NN ,@, their@PP$ impact on@IN pulmonary@JJ arterial@JJ hypertension@NN (@( PAH )@) be@VBZ unknown@JJ .@SENT
ACHE , NAV1 , TRPV1
INTERACT NAV1 TRPV1
these@DT datum@NNS demonstrate@VVP that@IN/that Nav1 @card@@CD blocker@NNS and@CC TRPV1 antagonist@NNS administer@VVN in@IN combination@NN produce@VVP an@DT additive@JJ effect@NN in@IN rat@NN pain@NN model@NNS .@SENT
REL , RELA
NOT INTERACT REL RELA
these@DT finding@NNS demonstrate@VVP that@IN/that within@IN the@DT same@JJ neuronal@JJ cell@NN ,@, the@DT balance@NN between@IN activation@NN of@IN p50/@JJ RelA and@CC C-@NP Rel -containing@NN complex@NNS fine@JJ tune@NNS the@DT threshold@NN of@IN neuron@NN vulnerability@NN to@TO the@DT ischaemic@JJ insult@NN .@SENT
CASP3 , TNF
INTERACT CASP3 TNF
for@IN TNF -induced@JJ apoptosis@NN ,@, the@DT anti-apoptotic@JJ effect@NN of@IN conidium@NNS of@IN all@DT isolate@NNS be@VBD find@VVN to@TO be@VB associate@VVN with@IN a@DT reduction@NN of@IN caspase @card@@CD in@IN human@JJ cell@NNS .@SENT
large , SPEN
INTERACT large SPEN
Spen be@VBZ regulate@VVN by@IN the@DT Notch@NP pathway@NN in@IN the@DT lymph@NN gland@NNS and@CC be@VBZ require@VVN for@IN Notch-dependent@JJ activation@NN of@IN a@DT large number@NN of@IN gene@NNS involve@VVN in@IN energy@NN metabolism@NN and@CC differentiation@NN .@SENT
CYP1A1 , GSTM1
INTERACT CYP1A1 GSTM1
previous@JJ study@NNS have@VHP implicate@VVN